An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials-Reference-Cited by-同舟云学术

An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials

Published:2017-04-05 Issue:6 Volume:27 Page:1054-1072
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Colin P.¹²,Delattre M.¹³,Minini P.⁴,Micallef S.⁵

Affiliation:

1. AgroParisTech, UMR 518 MIA, Paris, France

2. Statistical Science & Modeling, Sanofi R&D, Chilly-Mazarin, France

3. INRA, UMR 518 MIA, Paris, France

4. Biostatistiques, Sanofi R&D, Chilly-Mazarin, France

5. Clinical Pharmacometrics, Roche Pharma Research and Early Development, Basel, Switzerland

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543406.2017.1295248

Reference47 articles.

1. Bayesian Analysis of Binary and Polychotomous Response Data

2. Phase II failures: 2008–2010

3. The treatment versus experimentation dilemma in dose finding studies

4. Optimal sequential designs in phase I studies

5. A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose-Finding Trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and issues in bivariate endpoints in study designs of translational medicine;Journal of Hepatology;2022-12

2. Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial;Contemporary Clinical Trials Communications;2022-04

3. Optimal biological dose: a systematic review in cancer phase I clinical trials;BMC Cancer;2021-01-13

4. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study;The Lancet Respiratory Medicine;2017-11